225 related articles for article (PubMed ID: 25400133)
1. Serum Immunoglobulin G4 levels are elevated in patients with Graves' ophthalmopathy.
Bozkirli E; Bakiner OS; Ersozlu Bozkirli ED; Eksi Haydardedeoglu F; Sizmaz S; Torun AI; Ertorer ME
Clin Endocrinol (Oxf); 2015 Dec; 83(6):962-7. PubMed ID: 25400133
[TBL] [Abstract][Full Text] [Related]
2. Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy.
Yu SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Thyroid; 2017 Sep; 27(9):1185-1193. PubMed ID: 28805160
[TBL] [Abstract][Full Text] [Related]
3. IgG4 serum levels in Graves' orbitopathy.
Comi S; Lanzolla G; Cosentino G; Maglionico MN; Posarelli C; Menconi F; Santini F; Elisei R; Marinò M
J Endocrinol Invest; 2024 Jul; 47(7):1711-1717. PubMed ID: 38127192
[TBL] [Abstract][Full Text] [Related]
4. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
Marinò M; Rotondo Dottore G; Ionni I; Lanzolla G; Sabini E; Ricci D; Sframeli A; Mazzi B; Menconi F; Latrofa F; Vitti P; Marcocci C; Chiovato L
J Endocrinol Invest; 2019 Apr; 42(4):471-480. PubMed ID: 30132285
[TBL] [Abstract][Full Text] [Related]
5. Elevated serum immunoglobulin G4 levels in patients with Graves' disease and their clinical implications.
Takeshima K; Inaba H; Furukawa Y; Nishi M; Yamaoka H; Miyamoto W; Ota T; Doi A; Kawashima H; Ariyasu H; Wakasaki H; Furuta H; Nakao T; Sasaki H; Akamizu T
Thyroid; 2014 Apr; 24(4):736-43. PubMed ID: 24256421
[TBL] [Abstract][Full Text] [Related]
6. IgG4 as a Biomarker in Graves' Orbitopathy.
Olejarz M; Szczepanek-Parulska E; Dadej D; Sawicka-Gutaj N; Domin R; Ruchała M
Mediators Inflamm; 2021; 2021():5590471. PubMed ID: 34220335
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of serum immunoglobulin G4 in glucocorticoid therapy of Graves' ophthalmopathy.
Li Y; Luo B; Zhang J; Zhou X; Shao S; Xu W; Yang Y; Yuan G
Clin Endocrinol (Oxf); 2021 Oct; 95(4):657-667. PubMed ID: 33938028
[TBL] [Abstract][Full Text] [Related]
8. Nicotinamide phosphoribosyltransferase leukocyte overexpression in Graves' opthalmopathy.
Sawicka-Gutaj N; Budny B; Zybek-Kocik A; Sowiński J; Ziemnicka K; Waligórska-Stachura J; Ruchała M
Endocrine; 2016 Aug; 53(2):497-504. PubMed ID: 26767650
[TBL] [Abstract][Full Text] [Related]
9. Ocular Manifestations and Clinical Implications of Serum Immunoglobulin G4 Levels in Graves' Ophthalmopathy Patients.
Luo B; Yuan X; Wang W; Zhang J; Liu R; Hu W; Qi X; Xiang N; Chen L
Ocul Immunol Inflamm; 2022 Apr; 30(3):580-587. PubMed ID: 33054491
[TBL] [Abstract][Full Text] [Related]
10. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.
Lytton SD; Ponto KA; Kanitz M; Matheis N; Kohn LD; Kahaly GJ
J Clin Endocrinol Metab; 2010 May; 95(5):2123-31. PubMed ID: 20237164
[TBL] [Abstract][Full Text] [Related]
11. [Autoantibodies, immunoglobulins and cytokine profile in patients with graves' disease and Graves' orbitopathy].
Sviridenko NY; Bessmertnaya EG; Belovalova IM; Mikheenkov AA; Sheremeta MS; Nikankina LV; Malysheva NM
Probl Endokrinol (Mosk); 2020 Oct; 66(5):15-23. PubMed ID: 33369369
[TBL] [Abstract][Full Text] [Related]
12. Serum selenium status in Graves' disease with and without orbitopathy: a case-control study.
Khong JJ; Goldstein RF; Sanders KM; Schneider H; Pope J; Burdon KP; Craig JE; Ebeling PR
Clin Endocrinol (Oxf); 2014 Jun; 80(6):905-10. PubMed ID: 24372054
[TBL] [Abstract][Full Text] [Related]
13. [Distribution of IgG subclasses of TgAb and TPOAb in sera from patients with Graves' disease, Graves' disease plus Hashimoto's thyroiditis and Hashimoto's thyrotoxicosis].
Yuan S; Yu N; Gao Y; Huang W; He Y; Dong B; Lu G; Li M; Cai X; Peng D; Wang Y; Li T; Huang Y; Gao Y; Guo X; Shi B
Zhonghua Yi Xue Za Zhi; 2014 Jan; 94(2):110-4. PubMed ID: 24721350
[TBL] [Abstract][Full Text] [Related]
14. The potential markers involved in newly diagnosed graves' disease and the development of active graves' orbitopathy.
He M; Wang Y; Wang J; Sui J; Ding X; Chen Z; Zhang M; Zhao Y; Xie B; Shi B
Cytokine; 2020 Mar; 127():154998. PubMed ID: 31972501
[TBL] [Abstract][Full Text] [Related]
15. The relationship between serum adipocytokines and Graves' ophthalmopathy: A hospital-based study.
Kim BY; Mok JO; Kang SK; Jang SY; Jung CH; Kim CH
Endocr J; 2016 May; 63(5):425-30. PubMed ID: 26842711
[TBL] [Abstract][Full Text] [Related]
16. Changes in Serum Immunoglobulin G4 Levels in Patients with Newly Diagnosed Graves' Disease.
Hiratsuka I; Yamada H; Itoh M; Shibata M; Takayanagi T; Makino M; Sugimura Y; Hayakawa N; Hashimoto S; Suzuki A
Exp Clin Endocrinol Diabetes; 2020 Feb; 128(2):119-124. PubMed ID: 30235492
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of IL-29 in Euthyroid Patients with Graves' Orbitopathy: A Preliminary Study.
Falkowski B; Szczepanek-Parulska E; Sawicka-Gutaj N; Krygier A; Ruchala M
Mediators Inflamm; 2020; 2020():4748612. PubMed ID: 32694926
[TBL] [Abstract][Full Text] [Related]
18. CD4+ T cells and the Th1/Th2 imbalance are implicated in the pathogenesis of Graves' ophthalmopathy.
Xia N; Zhou S; Liang Y; Xiao C; Shen H; Pan H; Deng H; Wang N; Li QQ
Int J Mol Med; 2006 May; 17(5):911-6. PubMed ID: 16596280
[TBL] [Abstract][Full Text] [Related]
19. Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy.
De Bellis A; Di Martino S; Fiordelisi F; Muccitelli VI; Sinisi AA; Abbate GF; Gargano D; Bellastella A; Bizzarro A
J Clin Endocrinol Metab; 1998 Apr; 83(4):1222-5. PubMed ID: 9543145
[TBL] [Abstract][Full Text] [Related]
20. Circulating levels of miR-146a and IL-17 are significantly correlated with the clinical activity of Graves' ophthalmopathy.
Wei H; Guan M; Qin Y; Xie C; Fu X; Gao F; Xue Y
Endocr J; 2014; 61(11):1087-92. PubMed ID: 25100151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]